NAC for Sciatica? One Small Trial Raises a Real Question

N-acetylcysteine (NAC) may deserve research attention for acute sciatica caused by a herniated disc. In one randomized trial, adding 600 mg twice daily to naproxen improved pain, disability, and patient-rated change after four to eight weeks. The catch is substantial: the study included only 62 people, reported p-values rather than the size of the improvement, and has not been replicated.

That leaves NAC in an interesting but narrow category: a biologically plausible supplement with one positive clinical signal, not an established treatment for lumbar radiculopathy or neuropathic pain.

What the radiculopathy trial found

In a 2024 randomized controlled trial by Heidari et al., patients with acute lumbar radiculopathy caused by disc herniation received naproxen plus either NAC 600 mg twice daily (1,200 mg daily) or placebo for eight weeks. The study used an intention-to-treat analysis.

At the earlier two-to-four-week assessment, the groups did not differ significantly. At weeks four to eight, the NAC group had statistically better scores on the Visual Analogue Scale for pain and the Oswestry Disability Index, with p<0.001 for both. Clinical Global Impression of Change also favored NAC (p=0.011), as did Patient Global Impression of Change (p=0.043).

Those results matter because they concern symptoms and function, not merely a blood marker. Yet statistical significance does not tell us whether the difference was large enough for patients to feel meaningfully better. The available publication summary does not provide mean changes, between-group differences, confidence intervals, standardized effect sizes, or the proportion of participants who reached a clinically important improvement. A p-value cannot fill in those blanks.

The timing also invites two interpretations. NAC could require weeks of sustained use before it raises intracellular glutathione enough to affect nerve sensitization. Or a small trial could simply capture different recovery paths in a condition that often improves over time. The study cannot settle that question.

Why NAC might affect nerve pain

A herniated disc can irritate a nerve root through mechanical pressure and inflammation. Oxidative stress may contribute to that inflammatory signaling and to heightened nerve sensitivity. NAC can directly react with some reactive oxygen species and supplies cysteine, a building block the body uses to make glutathione, one of its main intracellular antioxidants.

Human pharmacology supports the narrower claim that oral NAC can affect glutathione biology. In a pilot trial of GlyNAC in older adults, glycine plus NAC corrected glutathione deficiency and improved several oxidative-stress and inflammation biomarkers over multiple weeks. That study did not test sciatica, did not pair NAC with an NSAID, and cannot establish pain relief. It does show that the proposed glutathione-repletion pathway is achievable in people.

At the cellular level, a 2025 in vitro study by Mulè et al. found that a formulation containing glutathione, NAC, and uridine monophosphate suppressed inflammatory mediators including TNF-α, IL-1β, IL-2, and IL-6. The experiment used a combination product in cells, not NAC alone in people with radiculopathy. It supports plausibility, not clinical efficacy. Cell studies are excellent at generating hypotheses and famously poor at filling prescriptions.

Burning mouth syndrome complicates the story

Researchers have also tested NAC in burning mouth syndrome (BMS), a chronic condition marked by burning, stinging, or tingling in the mouth without an identifiable lesion. BMS is thought to involve small-fiber nerve dysfunction and central sensitization; oxidative stress has been proposed as one contributor.

A 2025 randomized trial of oral NAC for BMS examined the same broad antioxidant hypothesis in a different neuropathic pain condition. The available abstract does not provide enough outcome data to estimate benefit or compare it with the radiculopathy trial. It therefore adds evidence that the question has been tested, not evidence that oral NAC works across neuropathic pain.

A separate 2025 randomized trial tested topically applied liquid NAC for BMS. Moving to a topical formulation may indicate that earlier systemic approaches did not produce a sufficiently convincing result to end the question. But that is an inference about research direction, not a reported null result from oral NAC. The topical route also does not test the systemic glutathione-restoration mechanism proposed for lumbar radiculopathy.

The two BMS trials should restrain any broad claim that NAC treats "nerve pain." Different nerves, disease processes, delivery routes, and outcome measures can produce different results. Three trials across two conditions are a research program, not a consensus.

Where the evidence can mislead

Small positive trials often overestimate the true benefit. With 62 participants, the radiculopathy trial is vulnerable to chance imbalances and inflated effect estimates. The abstract also describes repeated assessments across pain, disability, and global-impression outcomes. Multiple comparisons raise the probability that at least one apparently positive result occurs by chance unless the analysis plan clearly controls for them.

The delayed separation between groups is especially hard to interpret in acute radiculopathy. It fits a glutathione-related mechanism that might take time, but it also fits uneven natural recovery in a small sample. Without a larger replication trial that reports absolute changes and confidence intervals, readers cannot distinguish a clinically useful effect from a favorable statistical pattern.

There is also no direct comparison here with established adjunctive options for radiculopathy, such as gabapentinoids, oral corticosteroids, or epidural steroid injections. That does not prove NAC is inferior; it means nobody can benchmark its clinical value from these data.

A 2024 systematic review of dietary and supplement interventions for chronic neuropathic pain places NAC in a broader exploratory field, but the available review information does not yield an NAC-specific effect estimate. No guideline in this evidence base recommends NAC for lumbar radiculopathy, BMS, or neuropathic pain generally.

What to do with this information

NAC has one positive, small randomized trial as an add-on to naproxen for acute disc-related lumbar radiculopathy. It does not yet have the replication, effect-size reporting, or comparative data needed for a clinical recommendation.

People should not start NAC specifically to treat sciatica on the strength of this evidence. The study tested NAC alongside naproxen, not as a substitute for medical evaluation or standard care. New leg weakness, saddle numbness, loss of bladder or bowel control, fever, or severe worsening pain needs prompt medical assessment.

For someone already taking NAC for another reason, this trial offers a reason to watch future research, not a reason to expect reliable pain relief. The combination of NAC 1,200 mg daily with an NSAID has not been adequately characterized for safety in this back-pain population. Discuss it with a clinician or pharmacist, particularly if kidney disease, gastrointestinal bleeding risk, other medicines, or prolonged NSAID use are part of the picture.

The next useful study is straightforward: a larger, preregistered trial with clinically interpretable pain and disability differences, confidence intervals, complete adverse-event reporting, and independent replication. Until then, NAC for disc-related sciatica remains a hypothesis with one encouraging result.